GLP‑1 medications are delivering impressive weight loss and shifting the trajectory of patient health. Now, a wave of next‑generation multiagonists and novel antiobesity drugs — with more targets, better delivery, and efficacy that can rival surgery's — is on the horizon. 

1. Oral Options Are on the Way

   Some patients who avoid injections will soon have oral versions of GLP-1s as a delivery option. A phase 3 clinical trial of people taking oral semaglutide at 50 mg a day showed up to 15.1% weight loss compared to those who took a placebo. The oral, small-molecule, nonpeptide GLP-1 receptor agonist orforglipron has displayed promising results for weight loss and is currently in late-stage trials.

2. Triple Agonists Take It Further

   Retatrutide targets three different receptors: GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon, aiming to reduce appetite and increase fat burning. In a phase 2 trial, it led to up to 24.2% weight loss in just less than a year. Researchers note that the effectiveness of retatrutide can be compared to that of bariatric surgery.

3. New Combinations Target More Than Obesity

   Drugs like cagrilintide-semaglutide (CagriSema) and survodutide combine GLP-1s with other agents to enhance overall health outcomes. CagriSema preserves lean mass and improves cardiovascular markers. Survodutide may also help with metabolic dysfunction-associated steatohepatitis, a severe form of fatty liver disease, while promoting weight loss.

4. New Mechanisms Offer Alternatives

   Maridebart cafraglutide (MariTide) is a drug in development that blocks GIP while activating GLP-1. It may only require a monthly or bimonthly dose. Such alternatives could help patients who don’t respond to current therapies and increase their adherence to treatment.

5. The Clinician’s Toolbox Expands

   Although GLP-1s have proven successful for many, they are not “one size fits all” medications. With the continued advancement of these drugs, clinicians will have appealing alternatives to offer patients who have not had success with or have not tolerated GLP-1s.

Bottom line: The next generation of obesity drugs is more diverse and potentially more effective. New mechanisms, oral options, and multitargeted therapies will allow more personalized treatment for patients.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.